Jacobs Levy Equity Management
IMUC

Jacobs Levy Equity Management’s ImmunoCellular Therapeutics, Ltd. IMUC Stock Holding History

Jacobs Levy Equity Management’s Portfolio IMUC Stock Details IMUC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-9,152
Closed -$178K – 924
2015
Q1 		$178K Buy
9,152
+1,303
+17% +$32.7K ﹤0.01% 714
2014
Q4 		$229K Buy
+7,849
New +$226K ﹤0.01% 723

Other funds holding IMUC

SM
Sabby Management Miami Beach, Florida $111M AUM 74.4% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
B
Bailard Foster City, California $4.91B AUM 31.75% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
CC
Callan Capital La Jolla, California $1.35B AUM 8.35% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $177B AUM 39.86% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Jacobs Levy Equity Management's IMUC Position: Q2 2015 in Review

Jacobs Levy Equity Management sold out of ImmunoCellular Therapeutics, Ltd. (IMUC) in Q2 2015, closing a stake of 9,152 shares — an estimated $178K sold.

Jacobs Levy Equity Management first reported a position in IMUC in Q4 2014 and held it in 2 quarters. The position peaked at $229K in Q4 2014. 31 funds tracked by Wall St. Rank hold IMUC as of Q2 2015.

  • Jacobs Levy Equity Management reported no remaining ImmunoCellular Therapeutics, Ltd. position as of Q2 2015 after selling out during the quarter.
  • Jacobs Levy Equity Management sold 9,152 ImmunoCellular Therapeutics, Ltd. shares in Q2 2015, an estimated $178K.
  • Jacobs Levy Equity Management first reported a position in ImmunoCellular Therapeutics, Ltd. in Q4 2014 and held it in 2 quarters.
  • Jacobs Levy Equity Management's ImmunoCellular Therapeutics, Ltd. position peaked at $229K in Q4 2014.
  • 31 funds tracked by Wall St. Rank held ImmunoCellular Therapeutics, Ltd. as of Q2 2015.

Based on Jacobs Levy Equity Management's 13F filing for Q2 2015, filed 14 Aug 2015.